馃摙 #SCLC news: Amgen announced that a Phase 3 study evaluating its DLL3-targeting therapy as part of first-line maintenance treatment for patients with extensive-stage small cell lung cancer met its primary endpoint
鉃★笍 Learn more: amgen.ly/4ihHq5p
$AMGN
Amgen harnesses the best of biology and technology to fight the world鈥檚 toughest diseases.
馃敆 Guidelines: amgen.ly/RpcA3B

